Anthony M. Insogna

Career

Anthony M. Insogna leads Jones Day’s IP Practice of over 200 professionals worldwide handling complex IP litigation, patent, trademark and copyright strategies, and licensing for the world’s leading companies. Anthony has more than 30 years of experience handling patent litigation, global patent strategies, IP due diligence, and licensing for clients. A trusted advisor for leading life science companies on Hatch-Waxman, BPCIA and PTAB litigation, he is steeped in cutting-edge technologies, such as antibody drug conjugates, CAR-T, CRISPR based gene writing and editing, gene therapies, vaccines and more.

Anthony’s Hatch-Waxman representations include REVLIMID®, one of the world's top-selling drugs, Abraxane®, Pomalyst®, Bridion®, Focalin® and dozens of others. He has handled over 85 IPRs and PGRs in challenges to life sciences patents. For patentees, Anthony has achieved an institution denial rate of 76% (22% above the denial rate in life sciences IPRs and PGRs). For petitioners, he has achieved an institution rate well above the average in cases challenging life sciences patents.

Anthony is also representing ToolGen in two patent interferences involving CRISPR/Cas9 technology. In the biopharmaceutical sector, Anthony is currently developing worldwide patent portfolio strategies for several companies with late-stage clinical candidates for cancer treatments.